RxDoctor Payments Data

Frederick White, MD

Endocrinology, Diabetes & Metabolism · Abilene, TXNPI 1033141684

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 155 payments — averaging $12.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$972
  • Amgen$480
  • Medtronic$112
  • Canon Medical Systems USA, Inc.$38
  • Abbott$38
  • AstraZeneca$35
  • plus $283 from 11 others

What the payments were for

  • Food & beverage$1,94799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,959 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas

Medicare billing

Part B allowed, 2024
$498,100
Medicare patients
720
Services billed
20,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$132,876
Repatha SureclickEvolocumab154$88,459
JardianceEmpagliflozin68$69,354
TrulicityDulaglutide51$49,282
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/744$29,197
FarxigaDapagliflozin Propanediol25$26,785
Tresiba Flextouch U-100Insulin Degludec54$24,604
SynthroidLevothyroxine Sodium117$11,705
Cinacalcet Hcl13$9,429
Xigduo XrDapaglifloz Propaned/Metformin13$8,021
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,739
JanuviaSitagliptin Phosphate12$6,675
Desmopressin AcetateDesmopressin (Nonrefrigerated)16$5,905
NovologInsulin Aspart26$4,684
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$4,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$972$137,560130 claims
Lilly USA, LLCTrulicity$29$49,28251 claims
AstraZenecaFarxiga$35$26,78525 claims
AbbVieSynthroid, Armour Thyroid$26$13,815147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

Other endocrinology, diabetes & metabolism in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →